FDA

FDA
#Astellas Pharma #FDA #Orphan drugs #Paediatrics

FDA grants orphan and paediatric exclusivities for Cresemba

The US Food and Drug Administration (FDA) has granted orphan drug and paediatric exclusivity to Cresemba (isavuconazonium sulfate) for the treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM) in paediatric patients. In December 2023, Cresemba for injection was approved for paediatric patients one year of age and older and… Read More

#News #Regulatory

#Antibodies #Bispecific Antibodies #FDA #Monoclonal antibodies #Neuroscience #Oncology

New DDW Highlights podcast: 11 March 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  It was antibodies hitting the headlines this week, with the discovery of antibodies with… Read More

#News

Pancreatic cancer
#FDA #Fibrosis #iOnctura #Oncology #Orphan drugs #Pancreatic cancer

Orphan Drug Designation for first-in-class autotaxin cancer therapy

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to iOnctura for its autotaxin inhibitor cambritaxestat for the treatment of pancreatic cancer. After assessing its novel chemical and biological properties, including an attractive non-clinical safety and efficacy profile, the FDA has granted Orphan Drug Status, conferring… Read More

#Cancer Research #News #Regulatory

#Antibodies #Bispecific Antibodies #FDA #Monoclonal antibodies #Neuroscience #Oncology

This week in drug discovery (4-8 March) 

News round-up for 4-8 March by DDW Digital Content Editor Diana Spencer. It was antibodies hitting the headlines this week, with the discovery of antibodies with potential against a new influenza target, the launch of a Phase I trial to investigate a novel type of bispecific antibody, and… Read More

#News

Dementia
#Alzheimer's #Eli Lilly #FDA #Neurodegenerative disorders #Phase III trial

FDA advisory committee meeting delays approval of donanemab

The US Food and Drug Administration (FDA) has revealed plans to convene a meeting of the Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) to discuss the Phase III TRAILBLAZER-ALZ 2 trial. The trial evaluated the efficacy and safety of Eli Lilly’s donanemab in early symptomatic Alzheimer's disease. The… Read More

#News #Regulatory

Demyelination of neuron
#Antisense Oligonucleotides (ASOs) #FDA #Orphan drugs #Rare disease #SynaptixBio

FDA Orphan Drug Designation awarded to rare disease therapies

UK-based biotech SynaptixBio has secured a second Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA). The company received its first ODD in early 2023 for a therapeutic that targets Hypomyelination with Atrophy of the Basal ganglia and Cerebellum (H-ABC), the most severe form of TUBB4A leukodystrophy. Read More

#News #Regulatory

#Allergy #CHMP #FDA #Melanoma #Regulatory #Schizophrenia #Scleroderma

This week in drug discovery (26 Feb – 1 March) 

News round-up for 26 Feb – 1 March by DDW Digital Content Editor Diana Spencer. The news highlights this week all focus on regulatory decisions, both positive and negative. The first therapy was approved for allergic reactions to food, a drug for scleroderma secured Fast Track Designation, and… Read More

#News

FDA
#Adverse event #FDA #Myeloma #Oncology #Oncopeptides

FDA withdraws approval of Oncopeptides’ Pepaxto

The US Food and Drug Administration (FDA) has announced its final decision to withdraw approval of Pepaxto (melphalan flufenamide), despite an appeal by manufacturer Oncopeptides. The drug was originally approved for use in combination with dexamethasone to treat some patients with multiple myeloma. Approval was withdrawn as the confirmatory study… Read More

#News #Regulatory #Trending News

#FDA #Finance #GlobalData #Minerva Biosciences #Neuroscience #Schizophrenia

Minerva value plummets following FDA rejection of roluperidone

The stock market value of Minerva Biosciences has dropped nearly 60%, following the US Food and Drug administration (FDA) decision not to approve roluperidone for symptoms of schizophrenia. The company received a ‘Complete Response Letter’ from the FDA highlighting the clinical deficiencies in its new drug… Read More

#News #Trending News

Fibrous dysplasia disease
#Certa Therapeutics #FDA #Scleroderma #Sclerosis

Scleroderma drug gets fast-tracked in the US 

The US Food and Drug Administration (FDA) has granted Fast Track Designation for Certa Therapeutics’ investigational therapy FT011 for the treatment of systemic sclerosis (scleroderma).  The Fast Track Designation was granted based on results of a Phase II study which indicated that treatment of scleroderma patients with FT011 for 12 weeks resulted in… Read More

#News #Regulatory

Peanut butter
#Allergy #FDA #Monoclonal antibodies #National Institute of Allergy and Infectious Diseases #Phase III trial

FDA approves first medication to reduce allergic reactions

The US Food and Drug Administration (FDA) has approved monoclonal antibody Xolair (omalizumab) for immunoglobulin E-mediated food allergy in some adults and children one year or older for the reduction of allergic reactions (Type I). The FDA said that Xolair is intended for repeated use to reduce the risk of… Read More

#News #Regulatory

Non-small cell lung cancer
#AstraZeneca #FDA #Lung cancer #Non-small cell lung cancer (NSCLC) #Oncology #Phase III trial

Combination therapy reduced risk of lung cancer progression by 38%

The US Food and Drug Administration (FDA) has approved AstraZeneca’s osimertinib (Tagrisso) as a treatment for locally advanced or metastatic non-small cell lung cancer (la/mNSCLC). It is approved in combination with platinum-based chemotherapy for patients with la/mNSCLC whose tumours have EGFR exon 19 deletions or exon 21 L858R mutations. Efficacy… Read More

#News #Regulatory

Hands with frostbite
#Clinical trial #Eicos Sciences #FDA #Regulatory

First drug for severe frostbite helps prevent amputation

The US Food and Drug Administration (FDA) has approved Eicos Sciences’ Aurlumyn (iloprost) injection, the first FDA-approved medication to treat severe frostbite. “This approval provides patients with the first-ever treatment option for severe frostbite,” said Norman Stockbridge, Director of the Division of Cardiology and Nephrology in the FDA’s Center for… Read More

#News #Regulatory

T cells attacking cancer
#Cell and gene therapy #Cell therapy #FDA #Iovance #Melanoma #Oncology #Solid tumours

FDA approves first T cell therapy in solid tumours

The US Food and Drug Administration has approved Amtagvi (lifileucel), the first cellular therapy indicated for the treatment of metastatic, unresectable melanoma. It is approved for use in adults that have previously been treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or… Read More

#News #Regulatory #Trending News

Peptide
#Endocrinology #FDA #Oncology #Orano Med #RadioMedix #Radiopharmaceuticals

First targeted alpha therapy receives breakthrough designation

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to AlphaMedix (212Pb-DOTAMTATE) for the treatment of adult patients with unresectable or metastatic, progressive somatostatin receptor expressing gastroenteropancreatic neuroendocrine tumours (GEP-NETs) who are naïve to peptide receptor radionuclide therapy (PRRT). AlphaMedix is a targeted alpha therapy currently in… Read More

#Cancer Research #News #Regulatory

#AnaMar #Autoimmune disease #European Medicines Agency #FDA #Fibrotic disease #Orphan drugs

Dual-action treatment for fibrotic disease secures orphan drug status

AM1476, a first-in-class, peripheral-acting serotonin receptor antagonist, has been granted US and EU Orphan Drug Designation as an anti-fibrotic treatment for systemic sclerosis. AM1476 is a selective peripheral-acting 5-HT2B receptor small molecule antagonist that can be delivered orally. It has demonstrated efficacy in in vitro and in vivo models of… Read More

#News #Regulatory